Ovid Therapeutics Inc. (OVID)
Market Cap | 181.52M |
Revenue (ttm) | 1.50M |
Net Income (ttm) | -54.17M |
Shares Out | 70.49M |
EPS (ttm) | -0.77 |
PE Ratio | n/a |
Forward PE | 1.79 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 16,066 |
Open | 2.70 |
Previous Close | 2.70 |
Day's Range | 2.53 - 2.74 |
52-Week Range | 1.41 - 3.35 |
Beta | 1.10 |
Analysts | Buy |
Price Target | 4.85 (+87.26%) |
Earnings Date | May 8, 2023 |
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for OVID stock is "Buy." The 12-month stock price forecast is $4.85, which is an increase of 87.26% from the latest price.
News

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Li...

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...

Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines designed to conquer epilepsies and meaningfully improve ...

3 Biotech Stocks Under $10 to Add to Your Buy List
These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk. The post 3 Biotech Stocks Under $10 to Add to Your Buy List appeared first on ...

Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...

Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epileps...

Healx and Ovid Therapeutics to Enter Strategic Partnership
– Ovid to License Gaboxadol to Healx –

Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small molecules targeting the KCC2 transporter, inc...

Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results
NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologic...

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological d...

A Trio of Magic Formula Stock Picks
In order to increase your chances of beating the market, one method is to choose stocks that rank highly according to the "Magic Formula" criteria.

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities
Dr. Michael Poole to Join the Board of Directors